Management of Thyroid Hurthle Cell Carcinoma: A Single Centre Analysis

Hurthle cell carcinoma (HCC) is a rare neoplasm of the thyroid gland. There is paucity of medical literature available on this histological subtype compared to other thyroid disease and thus no consensus on optimal treatment. We conducted a single centre retrospective analysis of histologically diagnosed patients with HCC to demonstrate management of these cases and rate of recurrence. Data were collected for patients who were diagnosed with HCC between 2010 and 2022 in East Kent Hospitals University NHS Trust, UK. Our results found 8 patients diagnosed with HCC (2M:6F) with the most common presenting symptom being a neck lump. Six out of eight patients underwent radioiodine therapy post-surgery, although there is no consensus on benefits for this. None of our patients were found to have metastases or nodal involvement. Our analysis adds to the current literature on this rare topic and will be important when discussing treatment options of this disease in the future and could help to narrow the gap towards a consensus for treatment.